These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31056961)

  • 1. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England.
    Marsh SE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):155-168. PubMed ID: 31056961
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative review of the pharmacoeconomic guidelines in South Africa.
    Carapinha JL
    J Med Econ; 2017 Jan; 20(1):37-44. PubMed ID: 27564849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Technology Assessment-Informed Decision Making by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care in Germany and the National Institute for Health and Care Excellence in England: The Role of Budget Impact.
    Schaefer R; Hernández D; Bärnighausen T; Kolominsky-Rabas P; Schlander M
    Value Health; 2023 Jul; 26(7):1032-1044. PubMed ID: 36921901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
    Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
    Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making.
    Yagudina RI; Kulikov AU; Serpik VG; Ugrekhelidze DT
    Value Health Reg Issues; 2017 Sep; 13():61-66. PubMed ID: 29073991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
    Alshreef A; Jenks M; Green W; Dixon S
    Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 15. Health technology assessment in England and Wales.
    Stevens A; Milne R
    Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to country-specific guidelines among economic evaluations undertaken in three high-income and middle-income countries: a systematic review.
    Sharma D; Aggarwal AK; Wilkinson T; Isaranuwatchai W; Chauhan AS; Prinja S
    Int J Technol Assess Health Care; 2021 Jul; 37(1):e73. PubMed ID: 34193325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective.
    Earnshaw J; Lewis G
    Pharmacoeconomics; 2008; 26(9):725-7. PubMed ID: 18767892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.